- Home
- KLXE vs MAIA Comparison
KLXE vs MAIA Comparison
Compare KLXE & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLXE
- MAIA
- Stock Information
- Founded
- KLXE 2018
- MAIA 2018
- Country
- KLXE United States
- MAIA United States
- Employees
- KLXE N/A
- MAIA N/A
- Industry
- KLXE Oilfield Services/Equipment
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- KLXE Energy
- MAIA Health Care
- Exchange
- KLXE Nasdaq
- MAIA Nasdaq
- Market Cap
- KLXE 35.8M
- MAIA 46.7M
- IPO Year
- KLXE N/A
- MAIA 2022
- Fundamental
- Price
- KLXE $1.95
- MAIA $1.88
- Analyst Decision
- KLXE Hold
- MAIA
- Analyst Count
- KLXE 1
- MAIA 0
- Target Price
- KLXE $4.50
- MAIA N/A
- AVG Volume (30 Days)
- KLXE 288.6K
- MAIA 529.1K
- Earning Date
- KLXE 08-06-2025
- MAIA 08-08-2025
- Dividend Yield
- KLXE N/A
- MAIA N/A
- EPS Growth
- KLXE N/A
- MAIA N/A
- EPS
- KLXE N/A
- MAIA N/A
- Revenue
- KLXE $688,600,000.00
- MAIA N/A
- Revenue This Year
- KLXE N/A
- MAIA N/A
- Revenue Next Year
- KLXE $3.97
- MAIA N/A
- P/E Ratio
- KLXE N/A
- MAIA N/A
- Revenue Growth
- KLXE N/A
- MAIA N/A
- 52 Week Low
- KLXE $1.51
- MAIA $1.40
- 52 Week High
- KLXE $7.66
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- KLXE 46.16
- MAIA 56.41
- Support Level
- KLXE $1.85
- MAIA $1.80
- Resistance Level
- KLXE $2.02
- MAIA $2.15
- Average True Range (ATR)
- KLXE 0.18
- MAIA 0.13
- MACD
- KLXE -0.02
- MAIA 0.02
- Stochastic Oscillator
- KLXE 13.48
- MAIA 60.00
About KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.